Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03238534
Other study ID # ABO-NB-15
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date September 12, 2017
Est. completion date September 3, 2021

Study information

Verified date December 2021
Source Aboca Spa Societa' Agricola
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Comparison of Neobianacid® clinical efficacy to omeprazole in relief of heartburn or epigastric pain


Description:

Comparison of heartburn or epigastric pain severity following administration of Neobianacid® (Group B) or omeprazole (Group A) from day 0 to day 27. An ad-hoc placebo will be also administered in both treatment arms. Then, a following phase (day 28-55) will follows in which Neobianacid® will be administered (on demand) to both treatment arms.


Recruitment information / eligibility

Status Completed
Enrollment 275
Est. completion date September 3, 2021
Est. primary completion date September 3, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: 1. Male and female patients 18 - 70 years old (inclusive). 2. Patients presenting one or both the 2 following conditions: - Patients presenting heartburn who have been already diagnosed with uncomplicated gastroesophageal reflux disease (GERD) or whose symptoms are consistent with a clinical diagnosis of uncomplicated GERD. - Patients who have been already diagnosed with uncomplicated Epigastric Pain Syndrome (EPS) or whose symptoms are consistent with a clinical diagnosis of uncomplicated EPS according to Rome III criteria. 3. A gastroscopy is to be performed if not already performed during the previous 3 years and the symptomatology is unchanged. 4. Patients having a VAS score = 30mm and = 70mm (VAS related to heartburn/ epigastric pain) for at least 6 out of 14 days preceding the screening visit. 5. Postmenopausal women i.e. women who have not experienced a menstrual bleed for a minimum of 12 months or women who have undergone surgical sterilization (tubal closure or ovaries removal). Otherwise, necessity for women of childbearing potential to follow a reliable contraceptive treatment. 6. Ability of the patients (in the Investigator's opinion) to comprehend the full nature and purpose of the study including possible risks and side effects. 7. Patients who agree not to alter their diet in any way for the duration of the trial and to maintain it at steady state. 8. Patients who agree not to make any major lifestyle changes during the trial. 9. Consent to the study and willing to comply with all its procedures. 10. Chronic therapies (if not related to the gastroenterological pathologies object of the study, according to the opinion of Investigator) are allowed, if the regimen is maintained stable during the whole study. Exclusion Criteria: 1. Patients with heartburn/epigastric pain who have not previously responded to antacid or PPI. 2. Patients having a VAS score > 70mm (VAS related to heartburn/ epigastric pain) for at least 6 out of 14 days preceding the screening visit. 3. Patient presenting one of the following condition: 1. anemia; 2. chronic gastrointestinal bleeding; 3. antibiotic use, including antifungal and antimalarial medication within 2 months preceding the start of the study; 4. progressive unintentional weight loss; 5. persistent or recurrent vomiting; 6. epigastric mass; 7. acute episode with dyspnea, diaphoresis, or tachycardia; 8. anorexia; 9. nausea or vomiting; 10. dysphagia or odynophagia. 4. Patients under triple therapy or eradication therapy against Helicobacter pylori. 5. Patients using any drugs that could affect symptoms, such as NSAIDS, antacids, anti- secretory agents including proton pump inhibitors (other than the study products) and histamine H2-receptor antagonists or prokinetic or antiulcer agents, gastric mucosal protectants, anticholinergics and/or cholinergic agents. Moreover, the patients will be asked to avoid any drugs of the above mentioned since the beginning of the study (since pre-screening visit) until the end of the study. 6. Patients with the presence of the following conditions: erosive GERD, Barrett's oesophagus or oesophageal stricture, active or healing gastroduodenal ulcer (except scars) or any other GI disease, which is not mentioned in the inclusion criteria; history of gastric, duodenal or esophageal surgery; malignant disease of any kind; gallstone. Any chronic disease that may affect the gastrointestinal upper tract. 7. Patients with clinically significant liver disease (AST/SGOT, ALT/SGPT >2 upper limits of normal). 8. Patients with clinically significant renal disease (serum creatinine >1.5 mg/dl). 9. Patient having any other conditions or disease that the Investigator will consider non-appropriate to the study (any severe disease of another major body system other than GI tract). 10. Patients with porphyria, hypophosphatemia, cachexia. 11. Pregnant or nursing women or women planning to become pregnant during the study. 12. Patients with a history of alcohol or drug abuse. 13. Known hypersensitivity or intolerance to any components of the study products or rescue medication. 14. Subjects presenting contraindications to the study products or rescue medication, according to concerning Summaries of Product Characteristics (SPC), e.g. for omeprazole, patients suffering from rare hereditary problems of fructose intolerance, Glucose Galactose Malabsorption (GGM) or sucrase-isomaltase deficiency. 15. Patients being treated with any drug whose pharmacokinetics can interfere with the intake of omeprazole or magaldrate (e.g., for omeprazole, the active substances known as CYP2C19 or CYP3A4 inhibitors, as clarithromycin and voriconazole, or inductors, as rifampicin and St. John's wort, Hypericum, or both) or with any drug with which omeprazole, neobianacid or magaldrate are able to interact. 16. Patient participating to any investigational drug trial within 4 weeks before screening.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Neobianacid®
Oral administrations of Neobianacid® (30' after meals and on demand)
Drug:
Omeprazole 20mg
Daily administration Omeprazole 20mg (per os, 30' before breakfast).
Other:
Neobianacid® placebo
Oral administrations of Neobianacid® placebo (30' after meals and on demand)
Omeprazole placebo
Daily administration Omeprazole placebo (per os, 30' before breakfast).

Locations

Country Name City State
Italy Ospedale Civile San Salvatore L'Aquila
Italy Azienda Ospedaliera Santa Maria Goretti Latina Rome
Italy Policlinico San Matteo Pavia Fondazione IRCCS Pavia
Italy Azienda Ospedaliera Perugia Perugia
Italy Azienda Ospedaliera Sant'Andrea Rome
Italy Ospedale San Giovanni Addolorata Rome
Italy Ospedale Sandro Pertini Rome
Italy Ospedale Sant'Eugenio Rome
Italy Policlinico Umberto I Rome
Italy Policlinico Universitario A. Gemelli Rome
Italy Policlinico Universitario Campus Biomedico di Roma Rome
Italy Azienda Ospedaliera Universitaria San Giovanni di Dio e Ruggi d'Aragona Salerno

Sponsors (4)

Lead Sponsor Collaborator
Aboca Spa Societa' Agricola BMR Genomics, Doppel Farmaceutici, University of Roma La Sapienza

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Other intestinal microbiota characterization Characterization of the whole intestinal microbiota carried out by means of the analysis of faecal samples; Baseline and Day 28. Day-1 and Day28
Primary Heartburn or epigastric pain severity through treatment (Day-1 to Day13) Comparison of heartburn or epigastric pain severity by means of a 100mm VAS scale (from "no symptoms" to "overwhelming symptoms"); from Baseline to Day 13, between groups. Baseline is defined as Day -1 Day-1 to Day13
Secondary Heartburn or epigastric pain severity through treatment (Day-1 to Day7) Comparison of heartburn or epigastric pain severity by means of a 100mm VAS scale (from "no symptoms" to "overwhelming symptoms") from Baseline to Day 1, Day 3 and Day 7, between groups Day-1 to Day7
Secondary Heartburn or epigastric pain severity through treatment (Day14 to Day27) Assessment of heartburn or epigastric pain severity by means of a 100mm VAS scale (from "no symptoms" to "overwhelming symptoms"); from Day 14 to Day 27 between groups. Day14 to Day27
Secondary Assessment of of rescue medication use Assessment of use (starting date and quantity) of rescue medication (antacid); from Baseline to Day 13, from Day 14 to Day 27 and from Day 28 to Day 55, between groups. Day-1 to Day55
Secondary Tablets of Neobianacid® Vs. Neobianacid® placebo Day14 to Day27 Assessment of number of tablets of Neobianacid® on demand in comparison to Neobianacid® placebo on demand; from Day 14 to Day 27, between groups. Day14 to Day27
Secondary Tablets of Neobianacid® Vs. Neobianacid® placebo Day28 to Day55 Assessment of number of tablets of Neobianacid® on demand; from Day 28 to Day 55, between groups. Day28 to Day55
Secondary Improvement in symptomatology Improvement in symptomatology, by means of Gastrointestinal Symptom Rating Scale Questionnaire - GSRS; Day 14, Day 28 and Day 56 versus Baseline, between groups. Day-1 to Day56
Secondary Improvement in quality of life Improvement in quality of life, by means of Gastrointestinal Quality of Life Index - GIQLI questionnaire; Day 14, Day 28 and Day 56 versus Baseline, between groups. Day-1 to Day56
Secondary Evaluation of treatment Evaluation of treatment by means of Overall Treatment Evaluation - OTE; Day 14, 28 and 56, between groups. Day-1 to Day56
See also
  Status Clinical Trial Phase
Recruiting NCT06084572 - Prospective Evaluation of pH-impedance Tracings According to the Wingate Consensus, and Influence on GERD Classification According to the Lyon Consensus
Completed NCT03568825 - Response Surface Pathway Design With Two Interventional- and One Response Variable in Estimating Minimum Efficacy Dose N/A
Recruiting NCT04703374 - A Study to Compare PK, PD and Safety of CKD-382 in Healthy Subjects Phase 1
Completed NCT04120025 - Effectiveness of Diaphragmatic Breathing on Reflux Symptoms in Outpatients N/A
Withdrawn NCT04771247 - Endoscopic Cardiac Band Ligation for the Management of Refractory GERD After Laparoscopic Sleeve Gastrectomy N/A
Completed NCT02575287 - Minimal Injuries From Esophagus Detected by Optical Enhancement System™ Associated to Optical Magnification HD Scopes N/A
Completed NCT01710800 - Twenty-Four Hour Combined Multi-Channel Impedance and pH Ambulatory Monitoring: Impedance Reflux Episodes of Patients On and Off Proton Pump Inhibitor Therapy N/A
Completed NCT00287339 - The Utility of Nexium in Chronic Cough and Reflux Disease Phase 4
Completed NCT00287391 - Sleep Disorders and Gastroesophageal Reflux Disease (GERD) Phase 4
Completed NCT00629564 - An Open, Randomized, Two Way Crossover Study Comparing the Effect of 20mg Esomeprazole Administered Orally and Intravenously as a 15 Minute Infusion on Basal and Pentagastrin-Stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD) Phase 4
Completed NCT04243668 - ANTI REFLUX MUCOSAL ABLATION THERAPHY (ARMA) N/A
Completed NCT03558477 - PK/PD Clinical Trial of YYD601 in Healthy Adult Male Phase 1
Recruiting NCT05042063 - Acoustic Cough Monitoring for the Management of Patients With Known Respiratory Disease
Completed NCT05069493 - Long-term Follow-up After Hiatal Hernia Repair by Tension-free Mesh Closure or Simple Suturing
Terminated NCT04626232 - Comparison of the Sleeve Gastrectomy Technique With a Nissen Fundoplication Added to the Conventional Sleeve Gastrectomy Technique in Morbidly Obese Patients N/A
Recruiting NCT05974722 - Mesh Vs Pledgets for Repair of Paraesophageal Hernia N/A
Recruiting NCT05781347 - Stretta Versus Conservative Treatment in Obese and Non-obese N/A
Completed NCT06141577 - A Study to Compare Pharmacokinetics, Pharmacodynamics and Safety of UI059 and UIC202201 in Healthy Subjects Phase 1
Recruiting NCT05108038 - A Study to Evaluate the PK, PD and Safety of CKD-382 in Healthy Subjects Phase 1
Recruiting NCT02587910 - Melanole, a Dietary Supplement, for the Treatment of Gastroesophageal Reflux Disease Phase 2/Phase 3